trending Market Intelligence /marketintelligence/en/news-insights/trending/pqamzcakzlibmpsyxsqhlg2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

Biotron to raise about A$1.5M in rights issue

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Biotron to raise about A$1.5M in rights issue

Sydney's Biotron Ltd. is planning to raise about A$1.5 million via a rights offering.

Eligible shareholders will be offered 1 new share and 1 attaching listed option for every 4 existing shares they hold as of May 16.

The issue is priced at 1.5 Australian cents per share — a 42% discount to the one-month volume weighted average price of the company's stock.

Shareholders can apply for additional securities in excess of their entitlement, but allocations are not guaranteed. The issue is partially underwritten up to A$800,000.

Directors of the company have indicated their intention to participate in the issue.

Biotron plans to use the net proceeds for the expansion of its hepatitis B virus program and for general corporate purposes.

CPS Capital Group Pty. Ltd. is acting as lead manager and underwriter related to the issue.